Additional file 5 of NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes

Supplementary Table 1. Summary of NF1 alterations identified on next-generation sequencing in institutional cohort of 542 glioblastoma. Supplementary Table 2. Genomic correlates of NF1 alterations within institutional cohort of 542 glioblastoma. Only genes altered at a frequency > 5% were assessed. P-values were calculated with two-sided Fisher exact test. Supplementary Table 3. Genomic correlates of NF1 alterations within TCGA glioblastoma cohort. Only genes altered at a frequency > 5% were assessed. P-values were calculated with two-sided Fisher exact test. Supplementary Table 4. Genomic correlates of NF1 alterations within CPTAC glioblastoma cohort. Only genes altered at a frequency > 5% were assessed. P-values were calculated with two-sided Fisher exact test. Supplementary Table 5. Immunohistochemical correlates of NF1 genomic status in TMA cohort. Comparisons between categorical variables were performed using the Fisher’s Exact test, and two sample independent t-test was used to compare p53 and Ki67 % positivity between conditions. Supplementary Table 6. Immunohistochemical correlates of NF1 immunostaining in TMA cohort. Comparisons between categorical variables were performed using the Fisher’s Exact test. Supplementary Table 7. Baseline clinicodemographic features of TMA cohort and NF1 immunostaining subgroups. Supplementary Table 8. Univariable and multivariable Cox proportional hazards analysis of overall survival in TMA cohort. Supplementary Table 9. Genomic correlates of NFC immunostaining in subset of NF1-wildtype glioblastomas. Only genes altered at a frequency > 5% were assessed. P-values were calculated with two-sided Fisher exact test. Supplementary Table 10. IHC correlates of NFC immunostaining in subset of NF1-wildtype glioblastomas. Supplementary Table 11. Univariable and multivariable Cox proportional hazards analysis of overall survival in NF1-wildtype subset of TMA cohort.